;

79.90 EUR

Opening hours: 09:00 - 17:30 (Central European Standard Time: 12/24/2024 5:25:25 PM)
Exchange open, closes in 4 minutes
0.00 EUR (0.00%)
4.92 EUR (4.92%)
7.46 EUR (7.46%)
148.60 EUR (148.60%)
90.70 EUR (90.70%)
97.11 EUR (97.11%)
145.94 EUR (145.94%)
29.42 EUR (29.42%)

About Pharma Mar SA

Market Capitalization 1.37B

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Headquarters (address)

Avenida de los Reyes, 1

Madrid 28770

Spain

Phone34 91 846 60 00
Websitehttps://www.pharmamar.com
Employees509
SectorHealthcare
IndustryBiotechnology
TickerPHM
ExchangeMadrid Stock Exchange
CurrencyEUR
52 week range26.16 - 86.40
Market Capitalization1.37B
Dividend yield forward3.31 %
Dividend yield forward Spain (ID:221, base:120) 11.71 %
P/E trailing1.98K
P/E forward21.41
Price/Sale8.22
Price/Book7.61
Beta5.00
EPS5.00
EPS Spain (ID:221, base:143) 3.00

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Pharma Mar SA has raised their dividend 3.31 years in a row. This is below the 42121.883300 year average in the 'Biotechnology' industry

Compound Average Growth Rate 3 Years

Compound Average Growth Rate 3 Years: Pharma Mar SA has raised their dividend 10.63 years in a row. This is below the 23.957000 year average in the 'Biotechnology' industry

Payout Ratio

Payout Ratio: Pharma Mar SA has raised their dividend 1.58K years in a row. This is above the 148.467900 year average in the 'Biotechnology' industry

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Pharma Mar SA has raised their dividend 3.31 years in a row. This is below the 42121.883300 year average in the 'Biotechnology' industry

Compound Average Growth Rate 3 Years

Compound Average Growth Rate 3 Years: Pharma Mar SA has raised their dividend 10.63 years in a row. This is below the 23.957000 year average in the 'Biotechnology' industry

Payout Ratio

Payout Ratio: Pharma Mar SA has raised their dividend 1.58K years in a row. This is above the 148.467900 year average in the 'Biotechnology' industry

CleverShares.com|
2024 ©

1.0.9119.29486